Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Qilu Pharmaceutical on the deal. Qilu Pharmaceutical, one of the leading pharmaceutical companies in China (“Qilu”), announced its exclusive licensing agreement and strategic partnership...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised RBC Bearings Incorporated on the deal, while Kirkland & Ellis advised ABB. RBC Bearings Incorporated (Nasdaq: ROLL) announced its definitive agreement to acquire the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised 2U, Inc. on the deal while Goodwin Procter represented edX. 2U, Inc., a global leader in education technology, announced a definitive agreement to acquire...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Zai Lab Limited on the deal. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its broad strategic collaboration and license agreement with MacroGenics...
You must be a Standard 1 Year member to access this content.
Sidley Austin advised Sixth Street and Goldman Sachs on the deal while Goodwin Procter LLP represented Datavant. Ropes & Gray represented New Mountain Capital and its...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
You must be a Standard 1 Year member to access this content.
